Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01860339 · ClinicalTrials.gov registry record

Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease

A clinical trial of Huntington's Disease, sponsored by Peggy C Nopoulos.

Recruiting
Registry status
400
Enrollment target
6
Study locations

NCT01860339: Recruiting study of Huntington's Disease, sponsored by Peggy C Nopoulos.

NCT01860339 is a study of Huntington's Disease that is actively recruiting participants, run by Peggy C Nopoulos. The registered enrollment target is 400 participants, below the 4,744-participant average among 8 other Huntington's Disease trials with a reported enrollment target (92% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01860339, a study of Huntington's Disease, is actively recruiting participants, sponsored by Peggy C Nopoulos.

RECRUITING
Registry status
400 participants
Enrollment target
6
Study locations

Study Summary

Huntington's Disease (HD) is an autosomal dominant disease manifested in a triad of cognitive, psychiatric, and motor signs and symptoms. HD is caused by a triplet repeat (CAG)expansion in the gene Huntingtin (HTT). This disease has classically been conceptualized as a neurodegenerative disease. However, recent evidence suggests that abnormal brain development may play an important role in the etiology of HD. Huntingtin (HTT)is expressed during development and through life. In animal studies, the HTT gene has been shown to be vital for brain development. This suggests that a mutant form of HTT (gene-expanded or CAG repeats of 40 and above) would affect normal brain development. In addition, studies in adults who are gene-expanded for HD, but have not yet manifested the illness, (pre-HD subjects) have significant changes in the structure of their brain, even up to 20 years before onset of clinical diagnosis. How far back these changes are evident is unknown. One possibility is that these brain changes are present throughout life, due to changes in brain development,though initially associated with only subtle functional abnormalities. In an effort to better understand the developmental aspects of this brain disease, the current study proposes to evaluate brain structure and function in children, adolescents, and young adults (ages 6-30) who are at risk for developing HD - those who have a parent or grandparent with HD. Brain structure will be evaluating using Magnetic Resonance Imaging (MRI) with quantitative measures of the entire brain, cerebral cortex, as well as white matter integrity via Diffusion Tensor Imaging. Brain function will be assessed by cognitive tests, behavioral assessment, and physical and neurologic evaluation. Subjects that are gene-expanded (GE) will be compared to subjects who are gene non-expanded (GNE). Changes in brain structure and/or function in the GE group compared to the GNE group would lend support to the notion that this disease has

Primary Outcome

Magnetic Resonance Imaging (MRI) and Diffusion Tensor Imaging (DTI) data will be analyzed to assess brain structure based upon variables including global volume, total cerebral spinal fluid, subregion volumes, cortical surface anatomy including cortical depth, surface area and gyral shape, and symmetry between brain hemispheres, all in consideration of age, gender, and height. Results will be evaluated for comparative differences between the GE group and the GNE group. In addition, these measure

Conditions Studied

Study Locations (6)

California

  • University of California Davis - Sacramento

Iowa

  • University of Iowa Hospitals and Clinics, Department of Psychiatry - Iowa City

New York

  • Columbia University Medical Center - New York

Pennsylvania

  • Children's Hospital of Philadelphia with the University of Pennsylvania - Philadelphia

Tennessee

  • Vanderbilt University Medical Center - Nashville

Texas

  • University of Texas Health Science Center at Houston - Houston

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2005-07
Est. Completion 2026-08-31
Peggy C Nopoulos

2 total trials

What NCT01860339 shows while recruiting

NCT01860339 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 4,744-participant average among 8 other Huntington's Disease trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Huntington's Disease appearing as the primary indexed condition, and to 0 interventions.

NCT01860339 lists 6 locations in 6 states (California, Iowa, New York).

Frequently Asked Questions

What is clinical trial NCT01860339 about?

NCT01860339 is a clinical study titled "Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease". Huntington's Disease (HD) is an autosomal dominant disease manifested in a triad of cognitive, psychiatric, and motor signs and symptoms. HD is caused by a triplet repeat (CAG)expansion in the gene Huntingtin (HTT). This disease has classically been conceptualized as a neurodegenerative disease. How...

What is the current status of trial NCT01860339?

This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2005-07. Estimated completion is 2026-08-31.

What conditions does trial NCT01860339 study?

This clinical trial studies the following conditions: Huntington's Disease.

Who is sponsoring clinical trial NCT01860339?

This trial is sponsored by Peggy C Nopoulos, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01860339 being conducted?

This trial has 6 study locations across California, Iowa, New York, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Huntington's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01860339's enrollment target sits among peer trials

400 3rd of 8 higher than 6 of 8 other Huntington's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Huntington's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01860339, the US trial registry maintained by the National Library of Medicine. NCT01860339 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.